BioNTech

What’s new in cancer care across Europe in early 2024 (1 Jan – 5 Mar 2024): Advancements, Innovations, Research, Awareness

(IN BRIEF) In early 2024, Europe's medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like…

2 months ago

BioNTech and DualityBio Initiate Phase 3 Trial for HER2-Targeting ADC in Metastatic Breast Cancer

(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation…

3 months ago

BioNTech Inaugurates mRNA Vaccine Manufacturing Site in Rwanda, Aims to Boost Vaccine Equity in Africa

(IN BRIEF) BioNTech has achieved a significant milestone in expanding mRNA vaccine manufacturing in Africa with the inauguration of its…

4 months ago

BioNTech Enters Multi-Year Strategic Partnership with Victoria, Australia, to Boost Local mRNA Ecosystem

(IN BRIEF) BioNTech, a leading biotechnology company, has formalized a multi-year strategic partnership with the State of Victoria in Australia,…

5 months ago

Pfizer and BioNTech Report Promising Results for mRNA-Based Combination Vaccine Against Influenza and COVID-19

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine…

6 months ago

BioNTech to Announce Q3 2023 Financial Results and Host Innovation Series

(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th,…

6 months ago

BioNTech to Showcase Advances in Cancer Therapy at ESMO Congress 2023

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular…

6 months ago

BioNTech and CEPI Join Forces to Develop mRNA-Based Vaccine for mpox Prevention

(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an…

7 months ago

EU Clears BioNTech-Pfizer’s Adapted Comirnaty XBB.1.5 COVID-19 Vaccine for Fall Campaigns

(IN BRIEF) The European Union Commission has given the green light for the use of the adapted Comirnaty XBB.1.5 COVID-19…

8 months ago

EMA Recommends Pfizer and BioNTech’s Omicron XBB.1.5-Adapted COVID-19 Vaccine for Approval

(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency's Committee for Medicinal…

8 months ago

BioNTech Enhances Leadership Team with New Chief Legal Officer, James Ryan, to Drive Legal Strategy and Global Operations

(IN BRIEF) BioNTech SE, a biopharmaceutical company, has appointed James Ryan as Chief Legal Officer (CLO) and a member of…

9 months ago

BioNTech Q2 2023 update: Advances Oncology Pipeline and Prepares for Omicron-Adapted COVID-19 Vaccine Launch

(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the…

9 months ago

BioNTech Solidifies AI Advancements with InstaDeep Acquisition

(IN BRIEF) BioNTech SE has completed the acquisition of InstaDeep Ltd., a prominent AI and ML technology company. The acquisition…

9 months ago

OncoC4 licenses next-generation anti-CTLA-4 monoclonal antibody candidate to BioNTech

(IN BRIEF) BioNTech and OncoC4 have entered into an exclusive license and collaboration agreement to develop and commercialize OncoC4's anti-CTLA-4…

1 year ago

Siemens classé n°5 pour le nombre de brevets par l’Office européen des brevets ; numéro 1 en Allemagne

Siemens prend la cinquième place du classement des brevets de l'Office européen des brevets Vingtinventions par jour ouvrable au cours…

2 years ago

Siemens ranked #5 for number of patents by the European Patent Office; number 1 in Germany

Siemens takes fifth place in European Patent Office's patent ranking Twentyinventions per working day in fiscal 2021 Strong growth in…

2 years ago